NTRA News and Press, Natera Inc. From 08/15/23

2023-08-15 09:25:20 ET Summary Natera specializes in cfDNA technology, achieving 31.9% revenue growth in Q2 2023 and raising their annual outlook. Despite strong growth, Natera faces challenges with profitability, annual cash burn, and existing debts. Considering growth prospe...

2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...

2023-08-04 11:15:26 ET Shares of Natera (NASDAQ: NTRA) were soaring 18.7% higher at 11:04 a.m. ET on Friday. The big gain came after the DNA testing company announced its second-quarter results following the market close on Thursday. Natera reported Q2 revenue of $261.4 million,...

2023-08-04 10:09:12 ET Gainers: Alector ( ALEC ) +22% . OraSure Technologies ( OSUR ) +21% . Amneal Pharmaceuticals ( AMRX ) +20% . iRhythm Technologies ( IRTC ) +20% . Natera ( NTRA ) +16% . Losers: Mesoblast ( MESO ) ...

2023-08-03 22:08:04 ET Natera, Inc. (NTRA) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Michael Brophy – Chief Financial Officer Steve Chapman – Chief Executive Officer Solomon Moshkevich – General Manager-O...

2023-08-03 16:53:46 ET Natera press release ( NASDAQ: NTRA ): Q2 GAAP EPS of -$0.97 beats by $0.11 . Revenue of $261.4M (+31.9% Y/Y) beats by $19.87M . Outlook: Natera is raising its expectations for 2023 total revenue from $995 million to $1.015 billion to...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 ...

2023-08-02 17:35:58 ET Natera ( NASDAQ: NTRA ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, after market close. The consensus EPS Estimate is -$1.10 and the consensus Revenue Estimate is $241.53M (+21.9% Y/Y). Over the last 1 year, NTRA has b...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA. A live webcast and audio archive of t...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. ("NeoGenomics") for infringement of Natera's U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics&#...